Compare JPMorgan Chase & Co (JPM) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Medtronic PLC — how do they compare? JPMorgan Chase & Co trades at $339.1 (market cap $900.78B), while Medtronic PLC trades at $83.21 (market cap $106.61B). The key difference: JPMorgan Chase & Co is far larger — about 8.4× Medtronic PLC's market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| JPM | MDT | |
|---|---|---|
Market Cap | $900.78B | $106.61B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $346.91 | $105.35 |
52-Week Low | $282.84 | $73.75 |
Dividend Yield | 1.77% | 3.46% |
Enterprise Value | — | $125.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase trades at $341.10, down 0.6% on the day, with a bullish technical signal from moving averages and support at $339. The company reported strong Q1 and Q2 2026 earnings beats, with revenue growth from $169.4B in 2024 to $181.8B in 2025. Analyst consensus is Moderate Buy with a $374 price target, representing 9.6% upside potential. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings on April 14.
JPMorgan demonstrates solid fundamentals with consistent revenue growth and strong net income margins above 30%. The stock appears reasonably valued with a P/E of 14.6. Key risks include geopolitical tensions impacting banking operations and cybersecurity vulnerabilities from advanced AI systems. The bullish analyst sentiment and technical setup suggest potential for continued upside if earnings momentum persists.
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
